MRCP Respiratory: Mastering Tuberculosis Guidelines for Exams

admin
Infectious Diseases MRCP
1529 words • 7 min read

Article Content

Published by TalkingCases

Nov 20, 2026

Tuberculosis for MRCP: The Complete Guidelines Masterclass

Tuberculosis is one of those rare topics that touches every single component of the MRCP — Part 1 pharmacology loves rifampicin interactions, Part 2 loves the chest X-ray, CSF and sputum datasets, and PACES loves the six-month adherence consultation. England still notifies over 4,000 new cases every year, and notifications have climbed again since the pandemic, so TB is a live clinical problem — not an exam relic. Everything below is mapped to NICE guideline NG33, the document UK examiners build their mark schemes around.


Why TB Is Guaranteed Marks

  • Crosses disciplines: respiratory, infectious diseases, pharmacology, public health, ethics and communication all in one topic

  • High-frequency exam stems: night sweats and weight loss, deranged LFTs on treatment, sterile pyuria, basal meningitis

  • PACES favourite: counselling the newly diagnosed patient, managing side effects, discussing family screening


Pathology in 90 Seconds

  • Primary TB: first exposure produces a subpleural Ghon focus (mid/lower zone) plus draining hilar lymphadenopathy — the Ranke complex when calcified. It usually heals, but viable bacilli persist as latent infection.

  • Post-primary (reactivation) TB: occurs in the apical and posterior segments of the upper lobes — high oxygen tension favours reactivation. Cavitation is the radiological hallmark.

  • Haematogenous spread: miliary TB and seeding of the adrenals, bones, genitourinary tract and CNS.

  • Immune phenomena: erythema nodosum and phlyctenular conjunctivitis.

Risk factors examiners expect you to list unprompted: HIV, anti-TNF therapy and other immunosuppression, dialysis/CKD, diabetes, silicosis, malnutrition and vitamin D deficiency, alcohol excess, homelessness and prison, and birth or prolonged residence in a high-incidence country.

Classic exam trigger: commencing anti-TNF therapy — you must screen for and treat latent TB before starting the biologic.


Latent vs Active TB: Get the Framework Right

Feature Latent TB Active TB
Symptoms None Cough >3 weeks, haemoptysis, fever, night sweats, weight loss
Infectivity Not infectious Pulmonary and laryngeal disease contagious
Chest X-ray Normal or old scarring Opacification, cavitation, effusion, miliary nodules
Diagnostic test IGRA ± Mantoux Sputum AFB/culture/Xpert, histology

Testing for latent TB

  • IGRA is first-line in those aged 5 and over — it is unaffected by prior BCG vaccination

  • Mantoux (positive ≥5 mm induration) remains first-line in children under 5, with both tests recommended in immunosuppressed patients

  • Offer latent TB testing to: contacts of smear-positive cases, new entrants under 65 from high-incidence countries (≥150 per 100,000), people living with HIV, patients before anti-TNF therapy, and dialysis patients

Treating latent TB

  • 3 months of isoniazid + rifampicin (3HR) or 6 months of isoniazid (6H); 4 months of rifampicin alone is a recognised alternative

  • Always exclude active disease first — treating miliary TB with only two drugs is a potentially fatal error


Diagnosing Active Pulmonary TB

  1. Three sputum samples, at least one early morning, for AFB microscopy, mycobacterial culture (solid Löwenstein–Jensen medium takes up to 6 weeks; liquid MGIT around 2 weeks) and Xpert MTB/RIF Ultra — a same-day PCR that also detects rifampicin resistance

  2. Chest X-ray: upper-zone shadowing ± cavitation; finely nodular miliary pattern; scrutinise the apices

  3. Always test for HIV, and consider hepatitis B/C and diabetes screening

  4. If clinical suspicion is high, start empirical treatment while awaiting culture — never wait six weeks in a sick patient

  5. Histology shows caseating granulomas (contrast with non-caseating granulomas of sarcoidosis)

Extrapulmonary quick-reference

  • Lymph node (scrofula): commonest extrapulmonary site

  • Pleural: lymphocyte-rich exudative effusion; pleural biopsy is more sensitive than fluid culture

  • Skeletal: Pott's disease of the spine — vertebral collapse, paravertebral cold abscess, psoas abscess

  • Genitourinary: sterile pyuria — send three early-morning urines for AFB

  • CNS: basal meningitis (CSF shows high protein, very low glucose, lymphocytosis), tuberculomas, hydrocephalus, basal ganglia infarction

  • Pericardial: effusion progressing to constrictive pericarditis

  • Adrenal: a recognised cause of primary adrenal insufficiency

  • Miliary: look for choroidal tubercles on fundoscopy


Treatment: The RIPE Regimen

Standard therapy: 2 months of rifampicin + isoniazid + pyrazinamide + ethambutol, followed by 4 months of rifampicin + isoniazid — six months in total.

Drug Signature toxicity Exam pearl
Rifampicin Hepatitis; orange staining of all body fluids Potent CYP450 inducer — the interaction question
Isoniazid Peripheral neuropathy, hepatitis, lupus-like syndrome, sideroblastic anaemia Give pyridoxine (vitamin B6), especially in diabetes, pregnancy, HIV, CKD and alcohol excess
Pyrazinamide Hepatitis (the most hepatotoxic), hyperuricaemia and gout Confined to the intensive phase
Ethambutol Dose-dependent optic neuritis — reduced acuity, red–green colour desaturation Baseline Snellen acuity; dose-reduce in renal impairment

Duration adjustments

  • CNS TB: 12 months of treatment plus dexamethasone

  • Pericardial TB: 6 months plus prednisolone

  • Bone and joint TB: 6 months with specialist input

Special situations

  • Pregnancy and breastfeeding: treat with the standard four-drug regimen (all considered safe); avoid streptomycin (fetal ototoxicity)

  • HIV co-infection: treat TB promptly; ART is usually started within weeks (earlier when CD4 is very low); anticipate immune reconstitution inflammatory syndrome (IRIS) and major rifampicin–antiretroviral interactions

  • Jaundice or symptomatic hepatitis on treatment: stop the hepatotoxic drugs, involve TB services and microbiology, and reintroduce agents sequentially — never silently continue

  • Adherence problems: arrange directly observed therapy (DOT), often as supervised thrice-weekly dosing

Monitoring on treatment

  • Baseline FBC, U&E, LFTs, HIV test, hepatitis serology, HbA1c, visual acuity and weight (dosing is weight-based)

  • Monthly clinical review; repeat LFTs if nausea, jaundice or right upper quadrant pain develops, or if baseline risk is high

  • Monthly sputum until culture-negative, with follow-up for 12 months after completion


The Rifampicin Interaction Trap (Part 1 Gold)

Rifampicin powerfully induces hepatic CYP450 enzymes and reduces levels of:

  • Combined oral contraceptive pill — advise barrier contraception (the single most tested interaction)

  • Warfarin — INR falls; intensify monitoring

  • Sulfonylureas, levothyroxine and corticosteroids

  • Tacrolimus and ciclosporin, azole antifungals, HIV protease inhibitors

  • Methadone — can precipitate acute withdrawal

  • DOACs — avoid combinations where possible

Also warn patients that orange discolouration of urine, sweat and tears is expected — soft contact lenses may become permanently stained.


Public Health Duties You Must Verbalise in PACES

  • TB is a notifiable disease: suspected and confirmed cases must be notified to the local UKHSA health protection team — a legal duty under the Health Protection (Notification) Regulations 2010

  • TB services coordinate contact tracing and screening of close contacts of smear-positive pulmonary cases

  • BCG (a live vaccine) is contraindicated in known HIV-positive individuals

  • Isolate suspected pulmonary TB while infectivity is assessed; negative-pressure isolation if MDR-TB is possible


MDR-TB in a Paragraph

Resistance to isoniazid plus rifampicin defines MDR-TB; additional resistance to a fluoroquinolone and an injectable defines XDR-TB. A positive Xpert rifampicin-resistance result implies roughly a 90% probability of MDR-TB — escalate urgently to a specialist centre, never add a single drug to a failing regimen, and expect prolonged regimens containing agents such as bedaquiline, delamanid, linezolid and clofazimine.


How TB Appears in PACES

  • Station 5: counselling a new diagnosis — deliver the diagnosis with empathy, explain the six-month duration, side effects (including orange urine), family screening, notification, and adherence strategies. Variants include the patient with jaundice on treatment, or hazardous alcohol use compounding hepatotoxicity risk

  • Station 1: thoracoplasty scar, apical fibrosis, post-TB bronchiectasis, or an aspergilloma within an old cavity

  • Station 2: chronic cough with night sweats and weight loss — the differential you must actively construct


Ten High-Yield One-Liners

  1. Sterile pyuria in a high-risk patient means early-morning urines for AFB

  2. Anti-TNF therapy starts only after latent TB has been excluded or treated

  3. Caseating granulomas mean TB; non-caseating mean sarcoidosis

  4. Document Snellen acuity before ethambutol; red–green desaturation is the early sign of optic neuritis

  5. Pyridoxine prevents isoniazid-induced peripheral neuropathy

  6. Orange tears and urine mean rifampicin — and stained contact lenses

  7. Contraceptive failure on rifampicin is the classic Part 1 stem

  8. CSF with high protein, very low glucose and lymphocytes equals TB meningitis: 12 months of treatment plus dexamethasone

  9. Pericardial TB receives prednisolone; CNS TB receives dexamethasone

  10. Upper-zone fibrosis differential: old TB, sarcoidosis, silicosis, radiotherapy, ankylosing spondylitis


Key Takeaways

  • Master latent versus active disease: IGRA and who to test versus three sputums and Xpert

  • Know the RIPE regimen — 2 months of four drugs, 4 months of two — plus the CNS (12 months, dexamethasone) and pericardial (6 months, prednisolone) exceptions

  • The side-effect table (neuropathy, optic neuritis, hepatitis, gout) and the rifampicin interaction list are repeated exam currency

  • Notification and contact tracing are clinical duties, not optional extras — say them out loud in PACES

Approach TB as a connected story — risk factors, testing, treatment, toxicity, public health — and you will convert one of the commonest clinical scenarios in UK practice into reliable marks in every component of the MRCP.

Share

Turn this article into deliberate practice

Reading matters when it leads to action. Move into guided AI practice, open a free account, or continue through related blog content while the topic is still fresh.

Related Articles

Continue your medical education journey with these carefully curated insights

5 min read

Bloods Before Drugs: The MRCP Drug Monitoring Guide

Bloods Before Drugs: The MRCP Drug Monitoring GuideEvery MRCP sitting, a predictable family of questions appears: which blood test, how often, and what do you …

8 min read

Recent Advances in Diabetic Retinopathy: MRCP Ophthalmology Update

Recent Advances in Diabetic Retinopathy: MRCP Ophthalmology UpdateDiabetic retinopathy (DR) remains the leading cause of preventable blindness in working-age adults in the UK — and …

7 min read

AI Practice for MRCP Part 2: Clinical Vignette Mastery

AI Practice for MRCP Part 2: Clinical Vignette MasteryPassing MRCP(UK) Part 1 proves you can recall medicine. Part 2 Written tests something harder: whether you …

Join the Discussion

Share your thoughts and insights with the medical community

Comments